{"Abbreviation":["PCP"],"Absorption, Distribution and Excretion":"/Monkeys/ maintained a state of continuous intoxication which was sustained when the dose /of PCP/ was increased to 0.5 mg/kg. Substitution of saline after 58 days of exposure resulted in the appearance of numerous abstinence signs and symptoms including increased vocalizations, bruxism, oculomotor hyperactivity, diarrhea, refusal of preferred food, piloerection, and tremors. Less common signs included ear and facial twitches, priapism, abdominal contractions, emesis, and convulsions. The time course of withdrawal was characterized by an initial recovery from the PCP-induced intoxication at about 4 hr after saline substitution. Onset of hyper-responsive behaviors became evident at 8-12 hr, with the maximum number of symptoms occurring 12-15 hr post-substitution. The syndrome dissipated over 24 hr, however, and all withdrawal signs were immediately reversed by PCP (0.25 g/kg, iv). This study also showed that PCP blood levels were in the 105-280 mg/mL range during self administration, and declined to 0-12 mg/mL with saline substitution.","Aliases":["1-(1-Phenylcyclohexyl)piperidine","Angel dust","Fenciclidina","Piperidine, 1-(1-phenylcyclohexyl)-","Phencyclidinum","Phencycline","Cl-395","Phenylcyclidine","J4.441E","CHEBI:8058","CL 395","GP 121","Dtxsid6023446","Dust, Angel","Dtxcid703446","CL395","PCP","Elephant tranquilizer","Peace pill","Tic Tac","Killer weed","HOG","1-(Phenyl-1-cyclohexyl)piperidine","Supergrass","Cadillac","Crystal","Stardust","Surfer","Tranks","Whack","Magic mist","Zombie dust","Busy bee","DEA No. 7471","Cycline","Cyclones","Scuffle","Sherman","Superjoint","Superweed","Sheets","Snorts","Aurora borealis","Peace","Selma","Crystal joints","Goon","Phencyclidine-d5","Pits","Horse tracks","Monkey dust","Whacky weed","Wobble weed","Angel hair","Angel mist","Peace weed","Gorilla biscuits","Mint weed","Mint dew","Super Kool","Green tea leaves","Hog Dust","Horse tranquilizer","Kay Jay","Animal tranquilizer","Monkey tranquilizer","Mls002320664","HSDB 6472","Smr001338811","Unii-j1doi7uv76","Brn 1287039","Phencylidine","2pcp","Sernyl","Elysion","CJs","Sernylan","Epitope ID:180852","Oprea1_593450","Schembl42022","101887-87-0","5-20-02-00078","Chembl275528","GTPL4282","BDBM83449","cid_9795678","KCA12479","Pdsp1_001675","Pdsp2_001658","Akos015902745","Phencyclidine hydrochloride","DB03575","Ncgc00247332-01","NS00008732","Phencyclidine (PCP) 1.0 mg/ml in Methanol","1-(1-phenylcyclohexyl)piperidine;hydrochloride","C07575"],"Biological Half-Life":"PCP elimination from plasma is consistent with first-order kinetics with a half life of 7 to 26 hours.","Boiling Point":"136 °C","CAS":"77-10-1","ChemicalClasses":["arylcyclohexylpiperidine"],"Chirality":"achiral","Color/Form":"White, crystalline powder","Decomposition":"When heated to decomposition it emits toxic fumes of /nitrogen oxides/.","Drug Classes":["Breast Feeding","Lactation","Milk, Human","Excitatory Amino Acid Antagonists","Hallucinogens","Street Drugs"],"Drug Warnings":"The acute psychosis observed during the recovery phase of PCP anesthesia limits its clinical use. This bizarre behavior, characterized by confusion, vivid dreaming, and hallucinations, is termed an \"emergence reaction\". These reactions occur most frequently in middle-aged men, with a reported incidence of 17% to 30%. The most violent emergence reactions follow an intravenous dose of approximately 0.25 mg/kg (total: 20 mg) of phencyclidine. The mildest degrees of agitation produced by phencyclidine resemble the effects of ethanol intoxication.","DurationOfAction":"6 – 48 hours","EliminationHalfLife":"7 – 46 hours","Erowid Experience Reports":[{"Author":"mNi","Id":2952,"Title":"Decently Visual"},{"Author":"Zoidburg","Id":8071,"Title":"Dusting Up"},{"Author":"Pcp","Id":57778,"Title":"Outside of Myself"},{"Author":"PureConfusion","Id":26800,"Title":"Magic Carpet Ride"},{"Author":"sosxeno","Id":28387,"Title":"God Was a Tease"},{"Author":"DustBunny","Id":30093,"Title":"My Favorite Indulgence"},{"Author":"Justin","Id":32225,"Title":"Euphoric Insanity"},{"Author":"Kaliescope Eyes","Id":32419,"Title":"I Feel Like I'm in a Video Game"},{"Author":"Soma Sava","Id":34521,"Title":"New Years Nystagmus"},{"Author":"Sicarii Arafat","Id":26797,"Title":"Living Dead"},{"Author":"Chronique","Id":72367,"Title":"Intensely Stoned"},{"Author":"Blazed","Id":26289,"Title":"I Can Look, But I Can't See"},{"Author":"Ryan7","Id":24930,"Title":"PCP Experiences"},{"Author":"Ryan7","Id":22902,"Title":"The Good and the Bad"},{"Author":"Ryan M","Id":21856,"Title":"Surprised By The Effects And The Tastey Tastey Chicken"},{"Author":"d-doc hella sick","Id":74560,"Title":"Season of da Siccness"},{"Author":"Elusive","Id":20081,"Title":"This is Just Weed?"},{"Author":"Kyle","Id":19975,"Title":"The End of the World"},{"Author":"Dan.","Id":19157,"Title":"Our Legs Are Covered In Foam"},{"Author":"L","Id":69182,"Title":"What the Hell!?"},{"Author":"G-man","Id":37757,"Title":"My Old Friend"},{"Author":"Seezee-Three","Id":56317,"Title":"A Most Unusual Experience"},{"Author":"The Half Unlit","Id":55898,"Title":"Something Drawing Me to That Apple Pie"},{"Author":"Tyger","Id":55456,"Title":"A Visual Trip"},{"Author":"Kbomb","Id":55411,"Title":"Not As Horrific As It's Reputation Suggests"},{"Author":"Kay","Id":61586,"Title":"Stars Around The Moons"}],"Esters":[],"European Community (EC) Number":"621-588-0","Formating":[],"HMDB ID":"HMDB0256399","HeavyAtomCount":18,"Human Drugs":"Breast Feeding; Lactation; Milk, Human; Excitatory Amino Acid Antagonists; Hallucinogens; Street Drugs","Human Toxicity Values":"Lethal phencyclidine blood concentration: 100-500 ug/dL /From table/","IUPACName":"1-(1-phenylcyclohexyl)piperidine","Impurities":"Ether, cyclohexanol, isopropyl alcohol, ammonium chloride or hydroxide, and phenyllithium or phenylmagnesium halide may appear in the final product of phencyclidine synthesis ... 1-Piperidinocyclohexanecarbonitrile /PCC/ is a synthetic intermediate that has contaminated some batches of phencyclidine.","InChI":"InChI=1S/C17H25N/c1-4-10-16(11-5-1)17(12-6-2-7-13-17)18-14-8-3-9-15-18/h1,4-5,10-11H,2-3,6-9,12-15H2","InChIKey":"JTJMJGYZQZDUJJ-UHFFFAOYSA-N","Interactions":"Nicotine is a widely-abused drug, yet its primary reinforcing effect does not seem potent as other stimulants such as cocaine. Recent research on the contributing factors toward chronic use of nicotine-containing products has implicated the role of reinforcement-enhancing effects of nicotine. The present study investigates whether phencyclidine (PCP) may also possess a reinforcement-enhancement effect and how this may interact with the reinforcement-enhancement effect of nicotine. PCP was tested for two reasons: (1) it produces discrepant results on overall reward, similar to that seen with nicotine and (2) it may elucidate how other compounds may interact with the reinforcement-enhancement of nicotine. Adult male Sprague-Dawley rats were trained to lever press for brief visual stimulus presentations under fixed-ratio (FR) schedules of reinforcement and then were tested with nicotine (0.2 or 0.4 mg/kg) and/or PCP (2.0 mg/kg) over six increasing FR values. A selective increase in active lever-pressing for the visual stimulus with drug treatment was considered evidence of a reinforcement-enhancement effect. PCP and nicotine separately increased active lever pressing for a visual stimulus in a dose-dependent manner and across the different FR schedules. The addition of PCP to nicotine did not increase lever-pressing for the visual stimulus, possibly due to a ceiling effect. The effect of PCP may be driven largely by its locomotor stimulant effects, whereas the effect of nicotine was independent of locomotor stimulation. This dissociation emphasizes that distinct pharmacological properties contribute to the reinforcement-enhancement effects of substances.","KEGG Entries":[{"Id":"D05453","Interactions":[],"Synonyms":["Phencyclidine hydrochloride","PCP"]}],"MeSH Headers":[{"Id":"M0016495","Link":"https://id.nlm.nih.gov/mesh/M0016495.html","Name":"Phencyclidine","Ref":71},{"Id":"M0373872","Link":"https://id.nlm.nih.gov/mesh/M0373872.html","Name":"CL-395","Ref":73},{"Id":"DescTree","Link":"https://www.nlm.nih.gov/mesh/meshhome.html","Name":"MeSH Tree","Ref":74},{"Id":"PubMed from MeSH","Link":"https://www.nlm.nih.gov/mesh/meshhome.html","Name":null,"Ref":89},{"Id":"M0007520","Link":"https://id.nlm.nih.gov/mesh/M0007520.html","Name":"Enzyme Inhibitors","Ref":90},{"Id":"M0009763","Link":"https://id.nlm.nih.gov/mesh/M0009763.html","Name":"Hallucinogens","Ref":91},{"Id":"M0028006","Link":"https://id.nlm.nih.gov/mesh/M0028006.html","Name":"Excitatory Amino Acid Antagonists","Ref":92}],"MeSH Pharmacological Classification":[{"Id":"M0007520","Link":"https://id.nlm.nih.gov/mesh/M0007520.html","Name":"Enzyme Inhibitor","Ref":90},{"Id":"M0009763","Link":"https://id.nlm.nih.gov/mesh/M0009763.html","Name":"Hallucinogen","Ref":91},{"Id":"M0028006","Link":"https://id.nlm.nih.gov/mesh/M0028006.html","Name":"Excitatory Amino Acid Antagonist","Ref":92}],"Mechanism of Action":"The N-methyl-D-Aspartate (NMDA) receptor, a type of ionotropic receptor, is found on the dendrites of neurons and receives signals in the form of neurotransmitters. It is a major excitatory receptor in the brain. Normal physiological function requires that the activated receptor fluxes positive ions through the channel part of the receptor. PCP enters the ion channel from the outside of the neuron and binds, reversibly, to a site in the channel pore, blocking the flux of positive ions into the cell. PCP therefore inhibits depolarization of neurons and interferes with cognitive and other functions of the nervous system.","Melting Point":"46.5 °C","Metabolism/Metabolites":"PCP is metabolized mainly in the liver. Oxidative hydroxylation to the inactive monohydroxypiperidine is followed by glucuronidation to a more water-soluble, conjugated derivative that is then excreted in the urine as the major form of metabolism. Significant first-pass liver metabolism also occurs when the drug is ingested orally, as opposed to being smoked or injected. Approximately 10% of drug is excreted unchanged un the urine.","MolecularFormula":"C\u003csub\u003e17\u003c/sub\u003eH\u003csub\u003e25\u003c/sub\u003eN","MolecularWeight":"243.4 g/mol","Non-Human Toxicity Values":"LD50 Mouse oral 76.5 mg/kg","Odor":"Oily, slightly ammoniac","Pharmacodynamics":"Phencyclidine works primarily as an NMDA receptor antagonist, which blocks the activity of the NMDA Receptor.","PubChemId":6468,"Records":{"UNII":{"Impurities":[]}},"RefChem":"6117","RefCount":3,"RefCur":"","References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Phencyclidine","Name":"Phencyclidine","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q407324","Name":"Phencyclidine","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/DB03575","Name":"Phencyclidine","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/6468","Name":"Phencyclidine","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=77-10-1","Name":"Phencyclidine","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0256399","Name":"Phencyclidine","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C07575","Name":"Phencyclidine","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/J1DOI7UV76","Name":"Phencyclidine","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID6023446","Name":"Phencyclidine","Sub":false}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 6468, Phencyclidine. Accessed May 6, 2026. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/6468\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/6468\u003c/a\u003e","U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Phencyclidine. UNII: J1DOI7UV76. Global Substance Registration System. Accessed May 6, 2026. \u003ca href=https://gsrs.ncats.nih.gov/ginas/app/beta/substances/J1DOI7UV76\u003ehttps://gsrs.ncats.nih.gov/ginas/app/beta/substances/J1DOI7UV76\u003c/a\u003e"],"Reported Fatal Dose":"Lethal phencyclidine blood concentration: 100-500 ug/dL /From table/","SMILES":"C1CCC(CC1)(C2=CC=CC=C2)N3CCCCC3","SaltData":[{"AcidCount":1,"Amine":"Phencyclidine","AmineCount":1,"Formula":"Cl","Name":"hydrochloride","RName":"hydrochloride","Structure":"\u003csvg xmlns=\"http://www.w3.org/2000/svg\" preserveAspectRatio=\"none\" style=\"display:block\" viewBox=\"0 0 94.195 70.227\"\u003e\u003crect width=\"100%\" height=\"100%\" fill=\"#fff\"/\u003e\u003cdesc\u003eGenerated by the Chemistry Development Kit (http://github.com/cdk)\u003c/desc\u003e\u003cg fill=\"#1ff01f\" stroke=\"#000\" stroke-linecap=\"round\" stroke-linejoin=\"round\" stroke-width=\".7\"\u003e\u003cpath fill=\"#fff\" stroke=\"none\" d=\"M0 0h95v71H0z\"/\u003e\u003cg class=\"mol\"\u003e\u003cpath d=\"m35.631 69.188 13.197-7.622M48.828 61.566l.006-15.24M48.834 46.326l-13.19-7.618M35.644 38.708l-13.196 7.623M22.448 46.331l-.007 15.24M35.631 69.188l-13.19-7.617M35.644 38.708l-9.792-11.667\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m25.852 27.041 5.216-14.319M24.043 24.885l4.252-11.674\"/\u003e\u003c/g\u003e\u003cpath d=\"M31.068 12.722 21.276 1.055\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"M21.276 1.055 6.269 3.707M20.314 3.701 8.078 5.864\"/\u003e\u003c/g\u003e\u003cpath d=\"m6.269 3.707-5.216 14.32\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m1.053 18.027 9.792 11.667M3.826 17.538l7.981 9.51\"/\u003e\u003c/g\u003e\u003cpath d=\"m25.852 27.041-15.007 2.653M35.644 38.708l6.95-8.282M48.754 27.627l11.689 2.065M60.443 29.692l9.79-11.668M70.233 18.024l-5.217-14.32M65.016 3.704 50.009 1.053M50.009 1.053l-9.791 11.668M44.063 23.275l-3.845-10.554\" class=\"bond\"/\u003e\u003cpath fill=\"#3050f8\" stroke=\"none\" d=\"M47.376 29.49h-.721l-2.619-4.066h-.03l.03.595q.024.358.024.733v2.738h-.566v-4.899h.715l2.607 4.054h.03l-.018-.328-.024-.476q-.006-.262-.006-.482v-2.768h.578z\" class=\"atom\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"m42.594 30.426-3.475 4.141M48.754 27.627l5.845 1.033M44.063 23.275l-1.922-5.277\" class=\"hi\"/\u003e\u003c/g\u003e\u003cg class=\"mol\"\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M90.878 33.262q-.786 0-1.238.53-.453.524-.453 1.446 0 .911.417 1.447.423.53 1.268.53.322 0 .607-.054.292-.059.566-.143v.536q-.274.101-.566.149-.291.054-.696.054-.744 0-1.25-.31-.5-.31-.75-.875-.25-.572-.25-1.34 0-.744.267-1.309.274-.566.804-.881.53-.322 1.28-.322.78 0 1.351.286l-.244.524q-.226-.101-.506-.185-.274-.083-.607-.083m2.757 4.423h-.602V32.47h.602zM87.971 37.685h-.619v-2.286H84.84v2.286h-.614v-4.899h.614v2.071h2.512v-2.071h.619z\"/\u003e\u003c/g\u003e\u003c/g\u003e\u003c/g\u003e\u003c/svg\u003e","Title":"Phencyclidine hydrochloride","UNII":"V1JZQ7GDTX"}],"Salts":["hydrochloride"],"Scheduling":[{"gov":"Australia","ref":[],"schedule":"S8 substance"},{"gov":"Brazil","ref":[],"schedule":"A3 substance"},{"gov":"Canada","ref":[],"schedule":"Schedule I substance"},{"gov":"Germany","ref":[],"schedule":"Anlage I substance"},{"gov":"New Zealand","ref":[],"schedule":"Class A substance"},{"gov":"United Kingdom","ref":[],"schedule":"Class A substance"},{"act":"Controlled Substances Act (CSA)","gov":"United States","ref":[],"schedule":"Schedule I"},{"act":"Convention on Psychotropic Substances 1971","gov":"United Nations","ref":[],"schedule":"Schedule II drug"}],"Slang":["Good ","Rocket fuel "],"Solubility":"Soluble in ethanol","Stability/Shelf Life":"Stable under recommended storage conditions. /Phencyclidine hydrochloride/","StereoisomerData":[],"Stereoisomers":[],"Structure":"\u003csvg xmlns=\"http://www.w3.org/2000/svg\" preserveAspectRatio=\"none\" style=\"display:block\" viewBox=\"0 0 71.286 70.227\"\u003e\u003crect width=\"100%\" height=\"100%\" fill=\"#fff\"/\u003e\u003cdesc\u003eGenerated by the Chemistry Development Kit (http://github.com/cdk)\u003c/desc\u003e\u003cg fill=\"#3050f8\" stroke=\"#000\" stroke-linecap=\"round\" stroke-linejoin=\"round\" stroke-width=\".7\"\u003e\u003cpath fill=\"#fff\" stroke=\"none\" d=\"M0 0h72v71H0z\"/\u003e\u003cg class=\"mol\"\u003e\u003cpath d=\"m35.631 69.188 13.197-7.622M48.828 61.566l.006-15.24M48.834 46.326l-13.19-7.618M35.644 38.708l-13.196 7.623M22.448 46.331l-.007 15.24M35.631 69.188l-13.19-7.617M35.644 38.708l-9.792-11.667\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m25.852 27.041 5.216-14.319M24.043 24.885l4.252-11.674\"/\u003e\u003c/g\u003e\u003cpath d=\"M31.068 12.722 21.276 1.055\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"M21.276 1.055 6.269 3.707M20.314 3.701 8.078 5.864\"/\u003e\u003c/g\u003e\u003cpath d=\"m6.269 3.707-5.216 14.32\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m1.053 18.027 9.792 11.667M3.826 17.538l7.981 9.51\"/\u003e\u003c/g\u003e\u003cpath d=\"m25.852 27.041-15.007 2.653M35.644 38.708l6.95-8.282M48.754 27.627l11.689 2.065M60.443 29.692l9.79-11.668M70.233 18.024l-5.217-14.32M65.016 3.704 50.009 1.053M50.009 1.053l-9.791 11.668M44.063 23.275l-3.845-10.554\" class=\"bond\"/\u003e\u003cpath stroke=\"none\" d=\"M47.376 29.49h-.721l-2.619-4.066h-.03l.03.595q.024.358.024.733v2.738h-.566v-4.899h.715l2.607 4.054h.03l-.018-.328-.024-.476q-.006-.262-.006-.482v-2.768h.578z\" class=\"atom\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"m42.594 30.426-3.475 4.141M48.754 27.627l5.845 1.033M44.063 23.275l-1.922-5.277\" class=\"hi\"/\u003e\u003c/g\u003e\u003c/g\u003e\u003c/svg\u003e","Therapeutic Uses":"Enzyme Inhibitors; Hallucinogens; Excitatory Amino Acid Antagonists","Title":"Phencyclidine","UNII":"J1DOI7UV76","Wikidata":"Q407324","Wikipedia":"Phencyclidine","XLogP":3.6}